Investor Presentation • Jun 2, 2012
Investor Presentation
Open in ViewerOpens in native device viewer
Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.1 million individuals worldwide. Through its network of 3,119 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 253,041 patients around the globe. Fresenius Medical Care is also the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
…new targets of the growth strategy were adopted in September 2010. Thereby we follow up the previous strategy, continuing to pursue the strategic four paths consistently in a financially responsible way to consolidate our position as world market leader in dialysis:
| Net revenue | \$ 3,249 million |
+ 9% |
|---|---|---|
| Operating income (EBIT) | \$ 503 million |
+ 13% |
| Net income1 | \$ 244 million |
+ 10% |
| attributable to shareholders of Fresenius Medical Care AG & Co. KGaA | ||
| Earnings per share1 | \$ 0.80 |
+ 10% |
| Total assets2 | \$ 21,988 million |
|
| Operating cash flow3 | \$ 481 million |
|
| Employees2 | 82,979 | + 5% |
| Patients2 | 253,041 | + 17% |
| Clinics2 | 3,119 | + 13% |
| Treatments3 | 9.21 million | + 13% |
| 1 excluding investment gain |
2 by March 31, 2012
3 in the first quarter of 2012
Dr. Ben J. Lipps (Chairman) Dr. Gerd Krick (Chairman)
Dr. Emanuele Gatti William P. Johnston
| Net revenue | ~ \$14.0 billion |
|---|---|
| Net income* | ~ \$1.14 billion |
| Leverage ratio (Debt/EBITDA) | < 3.0 |
| Capital expenditures | ~ \$700 million |
| Acquisitions | ~ \$1.8 billion |
*incl. corporate of US\$ 8 m *This does not include the investment gain in the amount of approx. \$127 million in the first quarter of 2012.
| Ticker Symbols | Ordinary shares | Preference shares |
|---|---|---|
| Frankfurt Stock Exchange | FME | FME3 |
| New York Stock Exchange (NYSE) | FMS | FMS/P |
| Reuters: XETRA / Frankfurt Stock Exchange | FMEG.DE / FMEG.F | FMEG_p.DE / FMEG_p.F |
| Bloomberg | FME GY | FME3 GY |
| Security Identification Numbers | ||
| WKN | 578 580 | 578 583 |
| ISIN | DE 0005785802 | DE 0005785836 |
| CUSIP No. (NYSE) | 358029106 | 358029205 |
| Amount | Coupon % | Maturity |
|---|---|---|
| in million | ||
| \$ 1,200 | March 31, 2013 | |
| March 31, 2013 | ||
| March 31, 2013 | ||
| € 250 | 5.50% | July 15, 2016 |
| € 100 | 3-month-Euribor +3.50% | Oct. 15, 2016 |
| \$ 500 | 6.875% | July 15, 2017 |
| \$ 400 | 6.50% | September 15, 2018 |
| € 400 | 6.50% | September 15, 2018 |
| \$ 800 | 5.625% | July 31, 2019 |
| € 250 | 5.25% | July 31, 2019 |
| \$ 650 | 5.75% | February 15, 2021 |
| € 300 | 5.25% | February 15, 2021 |
| \$ 700 | 5.875% | January 31, 2022 |
| € 155 | October 27, 2012 | |
| € 45 | October 27, 2014 | |
| \$ 800 | July 31, 2014 | |
| \$ 1,8501 \$ 1,7501 |
at the beginning before amortisation and extension
| Event | Date |
|---|---|
| Report on First Quarter 2012: | |
| Quarterly Financial Report: | May 31, 2012 |
| Report on Second Quarter 2012: | |
| Earnings Release: | August 1, 2012 |
| Conference Call: | August 1, 2012 |
| Quarterly Financial Report: | August 31, 2012 |
| Report on Third Quarter 2012: | |
| Earnings Release: | October 31, 2012 |
| Conference Call: | October 31, 2012 |
| Quarterly Financial Report: | November 30, 2012 |
| Fresenius Medical Care AG & Co. KGaA Investor Relations & Corporate Communications |
||
|---|---|---|
| Else-Kröner-Straße 1 | 61352 Bad Homburg | |
| Oliver Maier | P:+49(0)6172-609-2525 | |
| Senior Vice President, Head of IR & CC |
F:+49(0)6172-609-2301 | |
| Gerrit Jost Vice President |
P:+49(0)6172-609-5216 | |
| North America Terry L. Morris Vice President |
P:+1-800-948-2538 F: +1-615-345-5605 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.